Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for hypereosinophilic syndrome
NL-OMON58716Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Time to first HES worsening/flare. Started Jun 2022; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NL-OMON58716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58716.